These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 16818817

  • 21. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E, Trinquart L, Otmani A, Waintraub X, Kacet S, Clémenty J, Chatellier G, Le Heuzey JY, Evaluation Médico-Economique du Défibrillateur Automatique Implantable (EVADEF) Investigators.
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [Abstract] [Full Text] [Related]

  • 22. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP, Hellkamp AS, Mark DB, Walsh MN, Poole JE, Anderson J, Johnson G, Lee KL, Bardy GH, SCD-HeFT Investigators.
    J Am Coll Cardiol; 2014 Jun 17; 63(23):2560-2568. PubMed ID: 24727258
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C, Mealing S, Hawkins N, Eaton J, Brown B, Daubert JC, REVERSE study group.
    Eur Heart J; 2011 Jul 17; 32(13):1631-9. PubMed ID: 21112898
    [Abstract] [Full Text] [Related]

  • 24. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
    Das M.
    Expert Rev Cardiovasc Ther; 2009 Feb 17; 7(2):181-95. PubMed ID: 19210214
    [Abstract] [Full Text] [Related]

  • 25. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
    Prystowsky EN.
    Rev Cardiovasc Med; 2003 Feb 17; 4 Suppl 2():S47-54. PubMed ID: 12776013
    [Abstract] [Full Text] [Related]

  • 26. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.
    Goldenberg I, Moss AJ, Hall WJ, McNitt S, Zareba W, Andrews ML, Cannom DS, Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Investigators.
    Circulation; 2006 Jun 20; 113(24):2810-7. PubMed ID: 16769917
    [Abstract] [Full Text] [Related]

  • 27. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction?
    Bond M, Mealing S, Anderson R, Dean J, Stein K, Taylor RS.
    Int J Cardiol; 2009 Nov 12; 137(3):206-15. PubMed ID: 18703244
    [Abstract] [Full Text] [Related]

  • 28. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial.
    Saxon LA, Bristow MR, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, Feldman AM, Galle E, Ecklund F.
    Circulation; 2006 Dec 19; 114(25):2766-72. PubMed ID: 17159063
    [Abstract] [Full Text] [Related]

  • 29. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?".
    Zecchin M, Merlo M, Pivetta A, Barbati G, Lutman C, Gregori D, Serdoz LV, Bardari S, Magnani S, Di Lenarda A, Proclemer A, Sinagra G.
    Am J Cardiol; 2012 Mar 01; 109(5):729-35. PubMed ID: 22176998
    [Abstract] [Full Text] [Related]

  • 30. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
    Au-Yeung WT, Reinhall PG, Poole JE, Anderson J, Johnson G, Fletcher RD, Moore HJ, Mark DB, Lee KL, Bardy GH.
    Heart Rhythm; 2015 Oct 01; 12(10):2058-66. PubMed ID: 26096609
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure.
    Chen L, Hay JW.
    Cardiovasc Drugs Ther; 2004 Mar 01; 18(2):161-70. PubMed ID: 15162078
    [Abstract] [Full Text] [Related]

  • 32. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H, Dalloul G, Hasan R, Daccarett M, Saba S, David S, Machado C.
    Arch Intern Med; 2009 Sep 14; 169(16):1500-6. PubMed ID: 19752408
    [Abstract] [Full Text] [Related]

  • 33. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Dickinson MG, Ip JH, Olshansky B, Hellkamp AS, Anderson J, Poole JE, Mark DB, Lee KL, Bardy GH, SCD-HeFT Investigators.
    Am Heart J; 2007 Apr 14; 153(4):573-8. PubMed ID: 17383296
    [Abstract] [Full Text] [Related]

  • 34. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
    Smith T, Jordaens L, Theuns DA, van Dessel PF, Wilde AA, Hunink MG.
    Eur Heart J; 2013 Jan 14; 34(3):211-9. PubMed ID: 22584647
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
    Tonkin AM, Eckermann S, White H, Friedlander D, Glasziou P, Magnus P, Kirby A, Mulray S, Denton M, Sallaberger M, Hunt D, Simes J, LIPID Study Group.
    Am Heart J; 2006 Jun 14; 151(6):1305-12. PubMed ID: 16781242
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness of the implantable cardioverter defibrillator.
    Hlatky MA, Sanders GD, Owens DK.
    Card Electrophysiol Rev; 2003 Dec 14; 7(4):479-82. PubMed ID: 15071279
    [Abstract] [Full Text] [Related]

  • 37. Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator--the EVADEF study.
    Marijon E, Trinquart L, Otmani A, Leclercq C, Fauchier L, Chevalier P, Klug D, Defaye P, Lellouche N, Mansourati J, Deharo JC, Sadoul N, Anselme F, Maury P, Davy JM, Extramiana F, Hidden-Lucet F, Probst V, Bordachar P, Mansour H, Chauvin M, Jouven X, Lavergne T, Chatellier G, Le Heuzey JY, EVADEF Investigators.
    Am Heart J; 2010 Apr 14; 159(4):659-664.e1. PubMed ID: 20362726
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
    Calvert MJ, Freemantle N, Yao G, Cleland JG, Billingham L, Daubert JC, Bryan S, CARE-HF investigators.
    Eur Heart J; 2005 Dec 14; 26(24):2681-8. PubMed ID: 16284203
    [Abstract] [Full Text] [Related]

  • 39. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.
    Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, Boehmer JP, Carlson MD, Frantz RP, McNulty SE, Rogers JG, Anderson J, Johnson GW, Walsh MN, Poole JE, Mark DB, Lee KL, Bardy GH.
    Circulation; 2009 Dec 01; 120(22):2170-6. PubMed ID: 19917887
    [Abstract] [Full Text] [Related]

  • 40. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
    Filion KB, Xie X, van der Avoort CJ, Dendukuri N, Brophy JM.
    Int J Technol Assess Health Care; 2009 Apr 01; 25(2):151-60. PubMed ID: 19331707
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.